There has been a shakeup in markets since Donald Trump’s election, and investors have been positioning their portfolios to ...
After catching up with Pfizer’s Chairman and CEO, CFO, Chief Scientific Officer and Chief Strategy and Innovation Officer at the firm’s healthcare conference, JPMorgan analyst ...
Stocks have gotten off to a mixed start in 2025, but a third straight year of gains isn’t out of the question.
CrowdStrike is back near highs despite crashing in July. Why Raymond James' David Cox calls it "immediately suspicious." ...
Pfizer Ltd. key Products/Revenue Segments include Pharmaceuticals, Sale of services, Scrap for the year ending 31-Mar-2024.For the quarter ended 30-09-2024, the company has reported a Standalone Total ...